Brokers Issue Forecasts for Pfizer FY2025 Earnings

Pfizer Inc. (NYSE:PFE - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Pfizer in a research report issued to clients and investors on Tuesday, April 22nd. Cantor Fitzgerald analyst C. Gould forecasts that the biopharmaceutical company will earn $2.99 per share for the year. Cantor Fitzgerald currently has a "Neutral" rating and a $24.00 price target on the stock. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share.

A number of other brokerages have also recently commented on PFE. Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group dropped their price target on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 8th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $29.57.

Pfizer Trading Down 0.7 %

PFE opened at $22.38 on Thursday. The stock has a market cap of $126.93 billion, a PE ratio of 15.87, a PEG ratio of 0.64 and a beta of 0.67. The business has a 50 day moving average of $24.69 and a 200-day moving average of $26.06. Pfizer has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same period last year, the company posted $0.10 EPS. The company's quarterly revenue was up 24.7% compared to the same quarter last year.

Institutional Trading of Pfizer

A number of hedge funds have recently bought and sold shares of the company. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter worth $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at $27,000. Gould Capital LLC increased its stake in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer during the fourth quarter valued at $28,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by insiders.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.69%. Pfizer's dividend payout ratio is currently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.